NCT00050531 - High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

August 31, 2015

Conditions

Leukemia, Myeloid, Chronic

Interventions

DRUG

Gleevec

400 mg orally twice daily.

DRUG

Peg-alpha interferon (Peg-Intron)

PEG-IFN 0.5 mcg/kg each week subcutaneously.

DRUG

Sargramostim (GM-CSF)

125 mcg/m\^2 three times per week subcutaneously.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston